Accueil   Agenda - News   Toutes les news PAGE 2018 MEETING: AN IN SILICO MODEL OF HEPATITIS B VIRUS PREDICTS PATIENTS RESPONSE TO ENYO PHARMA’S DRUG CANDIDATE EYP001

PAGE 2018 MEETING: AN IN SILICO MODEL OF HEPATITIS B VIRUS PREDICTS PATIENTS RESPONSE TO ENYO PHARMA’S DRUG CANDIDATE EYP001

 

  • NOVADISCOVERY presents first results from the in silico component of the exploratory clinical program initiated by ENYO Pharma on EYP001, a non-bile acid FXR receptor agonist currently in phase 1b trial for the treatment of chronic Hepatitis B.

 

  •  Applying NOVADISCOVERY’s WISE® technology platform, the in silico model successfully reproduces the pharmacokinetics & pharmacodynamics of EYP001.

 

  • The study further anticipates the best dose for optimum antiviral response.

 

  • These first results will be presented at the PAGE 2018 in Montreux, Switzerland.

 


Lyon, May 16th, 2018 - NOVADISCOVERY, a pioneer in in silico medicine, today announces that its in silico model and first analysis of the effect of EYP001 treatment on Hepatitis B virus (HBV) infected patients will be presented at the Population Approach Group in Europe (PAGE) Meeting, May 29th – June 1st, 2018, Montreux, Switzerland. EYP001 is a synthetic non-bile acid Farnesoid X-receptor (FXR) agonist currently under clinical development by ENYO Pharma for chronic HBV infection. Following on a collaboration agreement signed with ENYO Pharma, NOVADISCOVERY has built a mathematical disease model to simulate the effect of the compound on HBV-infected virtual patients.

 


NOVADISCOVERY has applied its proprietary WISE® technology platform (Whitebox In Silico Engine), an open ecosystem that combines the company’s expertise in modeling and simulation. The two-step process has involved building a model using the literature-based, community-driven knowledge management platform GitHealth (https://githealth.io) by integrating bile acids physiology, cholesterol metabolism, HBV replication and EYP001 mode of action (MoA), the latter based on non-clinical data. The SimWork® simulation platform was then used to implement and calibrate the model, before testing by a team blinded to clinical EYP001 data on a large cohort (10,000 HBV infected virtual patients).

 

 

Read the press release

En poursuivant votre navigation sur ce site, vous acceptez l'utilisation de cookies pour vous proposer des services et offres adaptés à vos centres d'intérêt. En savoir plus... Fermer